Alaunos Therapeutics, Inc.

NasdaqCM:TCRT Stock Report

Market Cap: US$3.8m

Alaunos Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Alaunos Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth28.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Oct 04

Alaunos posts 51% tumor reduction for lung cancer therapy

Sep 21

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Sep 15

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Aug 31

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Aug 15

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Jul 26
Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Apr 06
Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Dec 20
Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

Jun 19

ZIOPHARM records sharpest gain in nearly four months

Jun 09

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11
Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09
How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15
We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

Jan 14

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

Dec 21

Activist holder wins Ziopharm Oncology board seats

Dec 17

Ziopharm Oncology CFO to step down

Dec 14

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23
What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Nov 20

ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Ziopharm Oncology thumbs down on investor's call for board seats

Nov 02

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alaunos Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:TCRT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20240-12-12-12N/A
6/30/20240-19-17-17N/A
3/31/20240-27-23-23N/A
12/31/20230-35-30-30N/A
9/30/20230-36-30-30N/A
6/30/20233-37-30-30N/A
3/31/20233-38-31-31N/A
12/31/20223-38-29-29N/A
9/30/20223-40-38-37N/A
6/30/20220-54-41-41N/A
3/31/20220-67-57-54N/A
12/31/20210-79-65-61N/A
9/30/20210-90-70-63N/A
6/30/2021N/A-87-78-70N/A
3/31/2021N/A-83-72-62N/A
12/31/2020N/A-80-67-57N/A
9/30/2020N/A-73-58-52N/A
6/30/2020N/A-127-51-46N/A
3/31/2020N/A-123-41-41N/A
12/31/2019N/A-118-41-41N/A
9/30/2019N/A92-41-41N/A
6/30/2019N/A148-39-39N/A
3/31/2019N/A145-41-41N/A
12/31/20180137-50-49N/A
9/30/20182-76-51-50N/A
6/30/20183-75N/A-54N/A
3/31/20185-75N/A-59N/A
12/31/20176-73N/A-55N/A
9/30/20176-70N/A-56N/A
6/30/20176-67N/A-57N/A
3/31/20176-180N/A-57N/A
12/31/20167-172N/A-58N/A
9/30/20167-167N/A-69N/A
6/30/20167-171N/A-10N/A
3/31/20166-54N/A-6N/A
12/31/20154-120N/A0N/A
9/30/20153-121N/A14N/A
6/30/20152-109N/A-42N/A
3/31/20151-100N/A-38N/A
12/31/20141-32N/A-37N/A
9/30/20141-30N/A-36N/A
6/30/20141-41N/A-41N/A
3/31/20141-54N/A-50N/A
12/31/20131-57N/A-60N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if TCRT's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if TCRT's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if TCRT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if TCRT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if TCRT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TCRT's Return on Equity is forecast to be high in 3 years time


Discover growth companies